通过转录基因和代谢基因分析,通过饮食衍生PGG的代谢调节和抗高血糖特性
An-Nan Zhang1, Chengdi Huang1, Lili Yan1
1Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling, 712100, Shanxi, China. zhangq@nwsuaf.edu.cn.
Food & function
|May 26, 2023
概括
1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG) 是一种天然化合物,通过促进葡萄糖吸收,有助于降低血糖水平. 这项研究揭示了PGG.
科学领域:
- 代谢学和转录学.
- 分子生物学分子生物学
- 营养科学 营养科学
背景情况:
- 糖尿病是一种主要的全球健康问题.
- 饮食干预对于管理和预防糖尿病至关重要.
- 1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG) 是一种具有潜在健康益处的天然化合物.
研究的目的:
- 为了研究PGG的低血糖效应.
- 阐明PGG对葡萄糖代谢作用的分子机制.
- 在高葡萄糖环境中识别PGG调节的关键基因和代谢物.
主要方法:
- 斑马鱼模型用于高通量选.
- 斑马鱼幼虫的代谢和转录分析.
- 定量实时PCR (RT-qPCR) 用于基因表达的验证.
主要成果:
- PGG促进葡萄糖的吸收,并降低斑马鱼的血糖水平.
- PGG的干预恢复了四个关键基因 (fthl27,LOC110438965,plat,aacs) 和六个因高葡萄糖而改变的代谢物.
- 验证后的基因与斯芬戈辛和 (R) -3-基布他诺酸代谢有关,影响阿佩林,亡,亡和布他诺酸途径.
结论:
- PGG表现出显著的低血糖活性.
- PGG调节特定的代谢途径,对于葡萄糖调节至关重要.
- PGG代表了一种有前途的饮食分子,用于治疗代谢障碍.
相关概念视频
Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
Glucose Homeostasis: Regulation of Blood Glucose
1.8K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.8K
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
220
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
220
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306


